Entero Therapeutics, Inc. (NASDAQ:ENTO) Short Interest Up 48.8% in March

Entero Therapeutics, Inc. (NASDAQ:ENTO) was the target of a large increase in short interest in March. As of March 15th, there was short interest totalling 142,800 shares, an increase of 48.8% from the February 28th total of 96,000 shares. Currently, 3.1% of the shares of the stock are sold short. Based on an average daily trading volume, of 222,800 shares, the short-interest ratio is currently 0.6 days.

Entero Therapeutics Trading Up 5.3 %

ENTO traded up $0.03 during midday trading on Monday, hitting $0.51. The company had a trading volume of 23,517 shares, compared to its average volume of 380,401. Entero Therapeutics has a twelve month low of $0.19 and a twelve month high of $3.16. The firm’s 50-day simple moving average is $0.52 and its 200-day simple moving average is $0.53.

About Entero Therapeutics

Entero Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of targeted and orally delivered therapies for the treatment of patients with gastrointestinal diseases. The company's pipeline candidates include latiglutenase, a targeted oral biotherapeutic for celiac disease designed to breakdown gluten into non-immunogenic peptides, currently under Phase 2 studies; and capeserod, a selective 5-HT4 receptor partial agonist under Phase 1 studies for the treatment of gastroparesis.